Investment banking brothers, Michael and Yoël Zaoui, are set to take a UK start-up that uses artificial intelligence to develop drugs public through their blank-cheque company unveiled in June.
Odyssey Acquisition, the Zaoui's €300m special purpose acquisition company, will combine with BenevolentAI in a deal that values the company at €1.5bn, according to a statement from the firm.
The...
Read more on fnlondon.com